Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chris Pepper

Showing results (31-40 of 114) with videos related to

Pageof 12
Sort By:
Oncotarget|May 24, 2012
The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cellsElisabeth Walsby, Lawrence Pearce, Alan K Burnett, et al.
Haematologica|July 2, 2013
Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cellsRyan Wong, Chris Pepper, Paul Brennan, et al.
Blood|November 26, 2002
The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitroChris Pepper, Alun Thomas, Terry Hoy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 23, 2011
Expansion of a CD8(+)PD-1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progressionClaudia Nunes, Ryan Wong, Malcolm Mason, et al.
International Journal of Cancer|April 13, 2011
CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridolXiangrui Liu, Shenhua Shi, Frankie Lam, et al.
Postgraduate Medical Journal|October 30, 2020
Managing drug-induced QT prolongation in clinical practiceRani Khatib, Fatima R N Sabir, Caroline Omari, et al.
Oncotarget|January 13, 2017
Tumor cell migration is inhibited by a novel therapeutic strategy antagonizing the alpha-7 receptorChris Pepper, Henry Tu, Paul Morrill, et al.
Biochemical Society Transactions|July 4, 2025
Computational modelling of aggressive B-cell lymphomaEleanor S Jayawant, Aimilia Vareli, Andrea Pepper, et al.
Journal of Medicinal Chemistry|June 4, 2021
Single Diastereomers of the Clinical Anticancer ProTide Agents NUC-1031 and NUC-3373 Preferentially Target Cancer Stem Cells <i>In Vitro</i>Magdalena Slusarczyk, Michaela Serpi, Essam Ghazaly, et al.
BMJ Open Quality|April 17, 2023
Developing a post-myocardial infarction medicines optimisation clinic: core competencies for upskilling pharmacists and initial patient feedbackRuth Price, Franki Wilson, Alistair Hall, et al.
Pageof 12

Showing results (31-40 of 114) with videos related to

Sort By:
Pageof 12
Oncotarget|May 24, 2012
The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cellsElisabeth Walsby, Lawrence Pearce, Alan K Burnett, et al.
Haematologica|July 2, 2013
Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cellsRyan Wong, Chris Pepper, Paul Brennan, et al.
Blood|November 26, 2002
The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitroChris Pepper, Alun Thomas, Terry Hoy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 23, 2011
Expansion of a CD8(+)PD-1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progressionClaudia Nunes, Ryan Wong, Malcolm Mason, et al.
International Journal of Cancer|April 13, 2011
CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridolXiangrui Liu, Shenhua Shi, Frankie Lam, et al.
Postgraduate Medical Journal|October 30, 2020
Managing drug-induced QT prolongation in clinical practiceRani Khatib, Fatima R N Sabir, Caroline Omari, et al.
Oncotarget|January 13, 2017
Tumor cell migration is inhibited by a novel therapeutic strategy antagonizing the alpha-7 receptorChris Pepper, Henry Tu, Paul Morrill, et al.
Biochemical Society Transactions|July 4, 2025
Computational modelling of aggressive B-cell lymphomaEleanor S Jayawant, Aimilia Vareli, Andrea Pepper, et al.
Journal of Medicinal Chemistry|June 4, 2021
Single Diastereomers of the Clinical Anticancer ProTide Agents NUC-1031 and NUC-3373 Preferentially Target Cancer Stem Cells <i>In Vitro</i>Magdalena Slusarczyk, Michaela Serpi, Essam Ghazaly, et al.
BMJ Open Quality|April 17, 2023
Developing a post-myocardial infarction medicines optimisation clinic: core competencies for upskilling pharmacists and initial patient feedbackRuth Price, Franki Wilson, Alistair Hall, et al.
Pageof 12